Transcriptome-wide Analysis Associates ID2 Expression with Combined Pre- and Post-capillary Pulmonary Hypertension

Overview

Journal Sci Rep

Specialty Science

Date 2019 Dec 22

PMID 31862991

Citations 8

Authors

Meghan J Arwood

Nasim Vahabi

Christelle Lteif

Ravindra K Sharma

Roberto F Machado

Julio D Duarte

Affiliations

Soon will be listed here.

Abstract

Heart failure with preserved ejection fraction (HFpEF) patients who develop pulmonary hypertension (PH) have an increased risk of death, with combined pre- and post-capillary PH (CpcPH) having the highest risk. However, the mechanism behind PH development in HFpEF is poorly understood. We aimed to identify transcriptomic associations with PH development in HFpEF. Blood was collected from 30 HFpEF patients: 10 without PH, 10 with isolated post-capillary PH, and 10 with CpcPH. Gene expression measurements were completed using transcriptome-wide RNA sequencing. Gene expression differences were compared using a quasi-likelihood method adjusting for age, sex, race, and smoking-status. Biological pathways were compared using global gene expression differences. A replication in 34 additional heart failure patients and a validation in lung tissue from a representative mouse model were completed using quantitative PCR. Six differentially expressed genes were identified when comparing transcriptomics between subjects with CpcPH and those without PH. When tested in additional subjects, only the association with ID2 replicated. Consistent with clinical findings, Id2 expression was also upregulated in mice with HFpEF and PH. Pathway analysis identified proliferative and mitochondrial pathways associated with CpcPH. Thus, these patients may possess systemic pathophysiological differences similar to those observed in pulmonary arterial hypertension patients.

Citing Articles

Genetic variation in RYR1 is associated with heart failure progression and mortality in a diverse patient population.

Guerra L, Lteif C, Huang Y, Flohr R, Nogueira A, Gawronski B Front Cardiovasc Med. 2025; 12:1529114.

PMID: 40060969 PMC: 11885062. DOI: 10.3389/fcvm.2025.1529114.

Using Omics to Identify Novel Therapeutic Targets in Heart Failure.

Lteif C, Huang Y, Guerra L, Gawronski B, Duarte J Circ Genom Precis Med. 2024; 17(3):e004398.

PMID: 38766848 PMC: 11187651. DOI: 10.1161/CIRCGEN.123.004398.

Regulation of cardiac fibrosis in mice with TAC/DOCA-induced HFpEF by resistin-like molecule gamma and adenylate cyclase 1.

Liu D, Zeng F, Chen Z, Qin Z, Liu Z FEBS Open Bio. 2024; 14(7):1101-1115.

PMID: 38710658 PMC: 11216931. DOI: 10.1002/2211-5463.13813.

Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction.

Li G, Zhao H, Cheng Z, Liu J, Li G, Guo Y J Adv Res. 2024; 68:215-230.

PMID: 38346487 PMC: 11785561. DOI: 10.1016/j.jare.2024.02.006.

Clinical features do not identify risk of progression from isolated postcapillary pulmonary hypertension to combined pre- and postcapillary pulmonary hypertension.

Babu G, Annis J, Garry J, Freiberg M, Hemnes A, Brittain E Pulm Circ. 2023; 13(2):e12249.

PMID: 37332851 PMC: 10271598. DOI: 10.1002/pul2.12249.

References

Treguer K, Naye F, Thiebaud P, Fedou S, Soulet F, Theze N . Smooth muscle cell differentiation from human bone marrow: variations in cell type specific markers and Id gene expression in a new model of cell culture. Cell Biol Int. 2009; 33(6):621-31. DOI: 10.1016/j.cellbi.2009.02.003. View

Delgado J, Conde E, Sanchez V, Lopez-Rios F, Gomez-Sanchez M, Escribano P . Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005; 7(6):1011-6. DOI: 10.1016/j.ejheart.2004.10.021. View

Redfield M, Jacobsen S, Burnett Jr J, Mahoney D, Bailey K, Rodeheffer R . Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289(2):194-202. DOI: 10.1001/jama.289.2.194. View

Kowanetz M, Valcourt U, Bergstrom R, Heldin C, Moustakas A . Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol. 2004; 24(10):4241-54. PMC: 400464. DOI: 10.1128/MCB.24.10.4241-4254.2004. View

Hoeper M, Barbera J, Channick R, Hassoun P, Lang I, Manes A . Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S85-S96. DOI: 10.1016/j.jacc.2009.04.008. View

Grigioni F, Potena L, Galie N, Fallani F, Bigliardi M, Coccolo F . Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant. 2006; 25(10):1241-6. DOI: 10.1016/j.healun.2006.06.015. View

DAlessandro A, El Kasmi K, Plecita-Hlavata L, Jezek P, Li M, Zhang H . Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming. Antioxid Redox Signal. 2017; 28(3):230-250. PMC: 5737722. DOI: 10.1089/ars.2017.7217. View

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

Barnett C, De Marco T . Pulmonary hypertension associated with left-sided heart disease. Heart Fail Clin. 2012; 8(3):447-59. DOI: 10.1016/j.hfc.2012.04.009. View

10.

Michelakis E . Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications. Circ Res. 2006; 98(2):172-5. DOI: 10.1161/01.RES.0000204572.65400.a5. View

11.

Moya I, Umans L, Maas E, Pereira P, Beets K, Francis A . Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades. Dev Cell. 2012; 22(3):501-14. PMC: 4544746. DOI: 10.1016/j.devcel.2012.01.007. View

12.

Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A . Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev. 2013; 22(130):543-51. PMC: 9639182. DOI: 10.1183/09059180.00007513. View

13.

Yang J, Li X, Li Y, Southwood M, Ye L, Long L . Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2013; 305(4):L312-21. PMC: 3891012. DOI: 10.1152/ajplung.00054.2013. View

14.

Guazzi M, Arena R . Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol. 2010; 7(11):648-59. DOI: 10.1038/nrcardio.2010.144. View

15.

Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View

16.

Lam C, Roger V, Rodeheffer R, Borlaug B, Enders F, Redfield M . Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009; 53(13):1119-26. PMC: 2736110. DOI: 10.1016/j.jacc.2008.11.051. View

17.

Dweik R, Rounds S, Erzurum S, Archer S, Fagan K, Hassoun P . An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med. 2014; 189(3):345-55. PMC: 4291177. DOI: 10.1164/rccm.201311-1954ST. View

18.

Wang H, Yu Y, Guo R, Shi Y, Song M, Chen J . Inhibitor of DNA binding-1 promotes the migration and proliferation of endothelial progenitor cells in vitro. Mol Cell Biochem. 2009; 335(1-2):19-27. DOI: 10.1007/s11010-009-0236-9. View

19.

Duarte J, Kansal M, Desai A, Riden K, Arwood M, Yacob A . Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. Pulm Circ. 2018; 8(2):2045894018773049. PMC: 5946646. DOI: 10.1177/2045894018773049. View

20.

Assad T, Hemnes A, Larkin E, Glazer A, Xu M, Wells Q . Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. J Am Coll Cardiol. 2016; 68(23):2525-2536. PMC: 5157701. DOI: 10.1016/j.jacc.2016.09.942. View